FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to ophthalmology, and is intended for the treatment of age-related, complicated and post-traumatic cataracts of humans and animals. Eye drops for cataract treatment comprise methyl ethylpyridinol hydrochloride – 5.0–50.0 g; anhydrous sodium sulfite – 2.5 g; sodium benzoate – 2.0 g; potassium dihydrogen phosphate – 5.4 g; sodium hydrogen phosphate dodecahydrate – 6.5 g; water-soluble methylcellulose – 6.5 g; water for injections – up to 1 l. For the treatment of cataracts, said eye drops are instilled into the eye, 1-2 drops 3 times a day for 6 months.
EFFECT: use of a group of inventions can prevent cataract progression and loss of vision in patients.
2 cl, 3 tbl, 10 ex
| Title | Year | Author | Number | 
|---|---|---|---|
| EYE DROPS BASED ON PHARMACEUTICALLY TOLERABLE ADDITIVE SALTS OF ACID AND METHYL ETHYL ENCEPHABOL CONTAINING COMPOSITION OF VITAMINS B | 2013 | 
 | RU2528912C1 | 
| EYE DROPS BASED ON COMPOSITION OF PHARMACEUTICALLY ACCEPTABLE ADDITIVE ACID SALTS AND METHYLETHYL PYRIDONOL AND TAURINE CONTAINING COMPOSITION OF GROUP B VITAMINS | 2013 | 
 | RU2533276C1 | 
| NEW EYE DROPLETS FOR CONSERVATIVE TREATMENT AND PREVENTION OF THE AGE-RELATED NUCLEAR CATARACT | 2015 | 
 | RU2637875C2 | 
| DOSAGE FORM BASED ON BUTYLAMINOHYDROXYPROPOXYPHENOXYMETHYL METHYLOXADIAZOLE | 2014 | 
 | RU2585400C2 | 
| EYE DROPS FOR TREATING AGE-RELATED NUCLEAR CATARACT | 2019 | 
 | RU2720676C2 | 
| DISULFIRAM AND TAURINE-CONTAINING OPHTHALMOLOGICAL MEDICATION IN FORM OF EYE DROPS | 2012 | 
 | RU2485939C1 | 
| COMBINED OPHTHALMIC PREPARATION PRESENTED IN FORM OF EYE DROPS AND CONTAINING POLYHEXAMETHYLENE GUANIDINE AND TAURINE | 2012 | 
 | RU2513997C1 | 
| OPHTHALMIC PREPARATION IN THE FORM OF EYE DROPS FOR PREVENTING AND TREATING INFECTIOUS CONJUNCTIVITIS CAUSED BY BACTERIA AND VIRUSES | 2019 | 
 | RU2699377C1 | 
| EYE DROPS FOR CATARACT TREATMENT | 1993 | 
 | RU2071316C1 | 
| IMPROVED EYE DROPS FOR PREVENTION AND TREATMENT OF EARLY MANIFESTATIONS OF AGE-RELATED NUCLEAR CATARACT | 2020 | 
 | RU2748598C1 | 
Authors
Dates
2018-07-25—Published
2016-12-02—Filed